Amarin_Logo_JPEG.jpg
Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China
November 19, 2020 18:30 ET | Amarin Corporation plc
Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol (LDL-C) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose...
Amarin_Logo_JPEG.jpg
Multiple New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at American Heart Association’s Virtual Scientific Sessions 2020
November 18, 2020 07:00 ET | Amarin Corporation plc
Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effectiveness in reducing major adverse cardiovascular events (MACE) in studied...
Amarin_Logo_JPEG.jpg
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association’s Virtual Scientific Sessions 2020
November 13, 2020 10:00 ET | Amarin Corporation plc
VASCEPA®, compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events (MACE) in post hoc exploratory analyses of patients with a history of CABG...
Amarin Corporation plc Logo
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences
November 11, 2020 16:30 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is...
Amarin Corporation plc Logo
Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update
November 05, 2020 06:00 ET | Amarin Corporation plc
Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds Progress Continues Towards...
Amarin Corporation plc Logo
New VASCEPA® (Icosapent Ethyl)-Related Scientific Findings to Be Presented at American Heart Association’s Virtual Scientific Sessions 2020
October 29, 2020 07:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new scientific findings that add to the growing body of knowledge...
Amarin Corporation plc Logo
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function at Baseline in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Society of Nephrology (ASN) Kidney Week 2020
October 26, 2020 07:00 ET | Amarin Corporation plc
Patients with decreased renal function prior to treatment with VASCEPA or placebo had higher rates of cardiovascular events than the overall population studied in REDUCE-IT REDUCE-IT...
Amarin Corporation plc Logo
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride (TG) Levels Despite Well-Controlled Low-Density Lipoprotein (LDL)-Cholesterol
October 23, 2020 07:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of real-world evidence data at American Society of...
Amarin Corporation plc Logo
Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020
October 19, 2020 07:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior...
Amarin Corporation plc Logo
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at Transcatheter Cardiovascular Therapeutics (TCT) Connect 2020
October 15, 2020 16:30 ET | Amarin Corporation plc
VASCEPA®, compared with placebo, significantly reduced primary composite first and total MACE (major adverse cardiovascular events) in post hoc exploratory analyses of patients with a history of PCI...